Teladoc Health (NYSE:TDOC) Given New $10.00 Price Target at Canaccord Genuity Group

Teladoc Health (NYSE:TDOC) had its price target decreased by Canaccord Genuity Group from $11.00 to $10.00 in a research note published on Thursday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the health services provider’s stock.

A number of other equities analysts have also recently commented on TDOC. Citigroup lifted their target price on shares of Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a report on Tuesday, May 5th. Weiss Ratings upgraded shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Finally, Bank of America raised their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $7.50.

Teladoc Health Stock Down 28.4%

Shares of NYSE TDOC opened at $6.58 on Thursday. The business has a 50-day moving average price of $8.21 and a 200 day moving average price of $6.54. The stock has a market cap of $1.19 billion, a PE ratio of -6.64 and a beta of 2.10. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75. Teladoc Health has a 52-week low of $4.40 and a 52-week high of $9.89.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.03. Teladoc Health had a negative return on equity of 12.02% and a negative net margin of 7.13%.The company had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. During the same quarter in the previous year, the company posted ($0.19) earnings per share. The firm’s revenue was down 4.0% compared to the same quarter last year. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Equities research analysts forecast that Teladoc Health will post -0.92 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Carlos Nueno sold 6,196 shares of Teladoc Health stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $47,275.48. Following the transaction, the insider directly owned 57,671 shares in the company, valued at $440,029.73. This trade represents a 9.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $60,322.78. Following the completion of the transaction, the insider directly owned 110,261 shares in the company, valued at $841,291.43. This represents a 6.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 39,195 shares of company stock valued at $299,058 in the last ninety days. Company insiders own 0.70% of the company’s stock.

Institutional Trading of Teladoc Health

Several hedge funds and other institutional investors have recently made changes to their positions in TDOC. Jupiter Asset Management Ltd. raised its holdings in Teladoc Health by 293.9% during the fourth quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock worth $27,021,000 after purchasing an additional 2,880,008 shares in the last quarter. Quantinno Capital Management LP lifted its position in Teladoc Health by 128.0% in the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock valued at $14,287,000 after purchasing an additional 1,471,631 shares during the period. Pale Fire Capital SE boosted its holdings in Teladoc Health by 74.8% in the 1st quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock valued at $18,522,000 after purchasing an additional 1,454,288 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Teladoc Health by 23.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock valued at $53,260,000 after purchasing an additional 1,325,106 shares in the last quarter. Finally, Trexquant Investment LP acquired a new position in Teladoc Health during the 4th quarter worth approximately $9,156,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Teladoc Health News Summary

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter loss of $0.21 per share, better than the expected $0.24 loss. Integrated Care and international operations showed relative strength, helping offset weakness elsewhere. Teladoc Health Q2 Earnings Beat Estimates on Integrated Care Strength
• Positive Sentiment: Canaccord Genuity maintained a “buy” rating while lowering its price target from $11 to $10, implying substantial potential upside from recent trading levels. Unusual options activity also indicated increased call buying, although it is not a fundamental catalyst. Benzinga analyst and options activity report
• Neutral Sentiment: Management’s cost controls appear to be narrowing losses and supporting cash generation: second-quarter operating cash flow was approximately $64.7 million, while cash and equivalents totaled about $774.3 million. However, the company remains unprofitable. Do Teladoc’s Weaker Q2 Results Signal a Turning Point in Its Profit Path?
• Negative Sentiment: Second-quarter revenue fell 4% year over year to $606.9 million, below analysts’ approximately $615.4 million forecast. The revenue miss was more important to investors than the adjusted earnings beat because it signals continued difficulty producing top-line growth. Teladoc Stock Plummets on Revenue Miss, Lowered Outlook
• Negative Sentiment: The main pressure came from BetterHelp, where changing demand patterns reduced mental-health services revenue. Stronger Integrated Care performance did not fully offset the weakness. Teladoc tumbles on revenue forecast cut as BetterHelp demand shifts hurt
• Negative Sentiment: Teladoc issued a soft third-quarter outlook, forecasting revenue of $569 million to $609 million versus consensus of roughly $629 million, and an EPS loss of $0.20 to $0.30 versus an expected $0.17 loss. Full-year revenue guidance was also reduced to about $2.4 billion, below the $2.5 billion consensus. Why Teladoc Health Stock Is Dropping Following Soft Q3 Outlook

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.